Inhibikase Therapeutics, Inc. 8-K

What Happened

• On May 12, 2026, Inhibikase Therapeutics, Inc. (IKT) announced its financial results for the quarter ended March 31, 2026.
• The company furnished a press release dated May 12, 2026 as Exhibit 99.1 to the Form 8-K. The filing also includes the Inline XBRL cover page (Form 104).
• The company states the information in this Form 8-K (including the press release) is being furnished — not “filed” — and therefore is not subject to Section 18 liability or automatically incorporated by reference in other filings except where expressly stated.

Key Details

• Filing date: May 12, 2026.
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Exhibit furnished: 99.1 — May 12, 2026 press release with the quarterly results.
• Interactive data: 104 — Cover Page Interactive Data File embedded in the Inline XBRL document.

Why It Matters

• This 8-K signals the company has released its quarterly results; investors should review the furnished press release for revenue, earnings, cash position, and any operational updates or guidance that could affect the stock.
• The “furnished, not filed” designation limits certain legal liabilities and means the content isn’t automatically incorporated into other SEC filings unless specifically referenced.
• Retail investors should read the press release (Exhibit 99.1) and any subsequent SEC filings for the detailed financial figures and management commentary.